Clinical Trials Browser

Lymphoma, T-Cell, Peripheral × Gemcitabine × Clear all

NCT06522737 2026-02-11

TERZO

Phase 3 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT07234162 2025-11-18

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Phase 3 Recruiting

Lymphoma, T-Cell, Peripheral

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05105412 2024-07-08

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral

NCT06211881 2024-01-18

Chi-GVM Regimen for the Treatment of R/R PTCL

Phase NA Unknown

Lymphoma, T-Cell, Peripheral

NCT01846390 2023-08-04

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT05441761 2022-07-01

Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

Phase 1/2 Unknown

Lymphoma, T-Cell, Peripheral

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT02181218 2020-11-17

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Phase 4 Unknown

Lymphoma, T-Cell, Peripheral

NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Phase 2 Terminated

21 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT01822886 2019-10-14

FIL_GEMRO

Phase 2 Completed

20 enrolled 11 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 3 Completed

271 enrolled 25 charts

Lymphoma, T-Cell, Peripheral

NCT01307592 2014-01-10

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma